16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting JAK-1 and JAK-2, RAG2 or IL-6 could help treat Peutz-Jeghers syndrome, which involves the formation of benign gastrointestinal polyps. In a mouse model of the disease, systemic knockout of RAG2...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
16:04 , Jul 20, 2018 |  BC Week In Review  |  Company News

EUSA acquires global rights to J&J's Sylvant

Johnson & Johnson (NYSE:JNJ) granted EUSA Pharma Ltd. (Hemel Hempstead, U.K.) worldwide rights to Sylvant siltuximab for $115 million in cash. The chimeric mAb against IL-6 is approved in more than 40 countries, including the U.S....
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
22:48 , May 29, 2018 |  BC Extra  |  Preclinical News

IL-1 blockade to treat CAR T side effects

In a pair of papers published Monday in Nature Medicine, researchers from the Sloan Kettering Institute and the San Raffaele Hospital Scientific Institute suggest blocking the IL-1 receptor could help treat side effects of CAR...
00:46 , Apr 28, 2018 |  BioCentury  |  Strategy

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed, former...
22:46 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample and rat studies suggest inhibiting CD126 could help treat pulmonary arterial hypertension (PAH). In lung samples from lung transplant patients with idiopathic PAH or in a rat model of PAH, levels...
21:12 , Apr 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting MLL5 could help treat RNA viral infections. In primary mouse macrophages infected with vesicular stomatitis virus (VSV) or Sendai virus, knockout of MLL5 decreased levels of...
22:47 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting TRPM2 could help treat cognitive impairment caused by chronic cerebral hypoperfusion. In a mouse model of the disease, systemic knockout of TRPM2 increased recognition memory, cognitive performance, and myelin...
22:45 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting IL-6 could help treat glioblastoma. In patients, endothelial cell levels of IL-6 were higher in tumors than in normal brain tissue. In a mouse model of...